標(biāo)題: Titlebook: Contemporary Pharmacotherapy of Overactive Bladder; Lindsey Cox,Eric S. Rovner Book 2019 Springer Nature Switzerland AG 2019 voiding dysfu [打印本頁(yè)] 作者: Perforation 時(shí)間: 2025-3-21 19:52
書目名稱Contemporary Pharmacotherapy of Overactive Bladder影響因子(影響力)
書目名稱Contemporary Pharmacotherapy of Overactive Bladder影響因子(影響力)學(xué)科排名
書目名稱Contemporary Pharmacotherapy of Overactive Bladder網(wǎng)絡(luò)公開度
書目名稱Contemporary Pharmacotherapy of Overactive Bladder網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Contemporary Pharmacotherapy of Overactive Bladder被引頻次
書目名稱Contemporary Pharmacotherapy of Overactive Bladder被引頻次學(xué)科排名
書目名稱Contemporary Pharmacotherapy of Overactive Bladder年度引用
書目名稱Contemporary Pharmacotherapy of Overactive Bladder年度引用學(xué)科排名
書目名稱Contemporary Pharmacotherapy of Overactive Bladder讀者反饋
書目名稱Contemporary Pharmacotherapy of Overactive Bladder讀者反饋學(xué)科排名
作者: BORE 時(shí)間: 2025-3-21 23:38
Diagnosis of Overactive Bladder,ne the condition as it has evolved over the past few decades. We will then review the basis for establishing a diagnosis, which includes a thorough symptom assessment as well as physical exam and urine studies. The use of adjunctive tests will also be reviewed, although their utility is limited in t作者: 貴族 時(shí)間: 2025-3-22 03:34
The Placebo Effect in Overactive Bladder Syndrome,ases and conditions. Some of the popular theories explaining the placebo effect are a “regression to the mean,” “expectancy theory,” “classical conditioning” theory, “context effect,” “meaning response,” and learned response theory. The effect of placebo in overactive bladder syndrome (OAB) has been作者: 彩色 時(shí)間: 2025-3-22 05:12 作者: 廚師 時(shí)間: 2025-3-22 11:20
National and International Guidelines for Overactive Bladder,atrics, neurology, gynecology, and urology, are involved in the diagnosis and management of a wide range of patients who present with symptoms of OAB. Several urologic, urogynecologic, geriatric societies and other organizations have developed guidelines for the evaluation and pharmacologic treatmen作者: 后退 時(shí)間: 2025-3-22 14:41
Antimuscarinic Pharmacotherapy for Overactive Bladder, by acetylcholine, which is released from cholinergic parasympathetic nerves. Antimuscarinic agents work during the storage phase of the micturition cycle to reduce involuntary bladder contractions and the sensation of urgency. A variety of antimuscarinics are available for use in the treatment of o作者: 后退 時(shí)間: 2025-3-22 21:08
,β3-Agonists for Overactive Bladder,tients, efficacy is not seen in all, and the side effect profile may result in decreased use. Mirabegron, a β3-adrenoceptor agonist, has been established as an alternative therapy. This chapter aims to review the history of mirabegron in addition to drug safety, efficacy, and reliability in a divers作者: 細(xì)節(jié) 時(shí)間: 2025-3-23 01:17 作者: 在駕駛 時(shí)間: 2025-3-23 04:40 作者: Friction 時(shí)間: 2025-3-23 05:55
Pharmacotherapy for Nocturia,ssion of the indications and efficacy of different classes of medications used to treat nocturia. Nocturia, defined as voiding that occurs during the hours of sleep, is common and bothersome. The underlying causes are multiple and diverse. Determining the underlying etiology is essential for choosin作者: concise 時(shí)間: 2025-3-23 11:21
Intravesical Chemodenervation and Toxins,ts fail. Intravesical therapy with botulinum neurotoxin should be introduced as a third-line treatment option in those OAB patients refractory to oral therapy or intolerant to its systemic side effects. The popularity of intravesical therapy with botulinum toxin has continuously increased due to the作者: 他很靈活 時(shí)間: 2025-3-23 14:37 作者: iodides 時(shí)間: 2025-3-23 20:13 作者: BROW 時(shí)間: 2025-3-23 22:49
Considerations in Pediatric Overactive Bladder,urologic abnormality. This troublesome condition has a prevalence of as high as 15–20% of the pediatric population, with 2–4% of 7-year-old children reporting incontinence episodes at least once a week. The main objectives of treatment are to normalize the micturition pattern, bladder and pelvic flo作者: Fsh238 時(shí)間: 2025-3-24 03:59 作者: 障礙 時(shí)間: 2025-3-24 07:00
Considerations in the Medically Complex and Frail Elderly,h significant adverse consequences in terms of quality of life and health outcomes. OAB management in this group of patients requires the treating clinician to take a broader view of the condition and its effect on the patient. The underlying physiological change in the lower urinary tract, coupled 作者: 音樂會(huì) 時(shí)間: 2025-3-24 11:42
Individualizing Drug Therapy,linergic drugs and β3-agonists (mirabegron). Both classes of medications are effective in controlling the symptoms associated with OAB; however, they may produce side effects that may limit successful therapy. Successful therapy is dependent upon patient’s compliance, and thus individualizing drug t作者: LAY 時(shí)間: 2025-3-24 15:18
Quality Assessment in View of System Theory, that is expeditious, easy to understand, complete, and provides a thorough assessment of the patient satisfaction or outcome. Providers may consider utilizing shared decision-making to set realistic expectations and choose a practical outcome measure specific to one’s clinical practice to optimize patient care and satisfaction.作者: electrolyte 時(shí)間: 2025-3-24 19:09 作者: Conquest 時(shí)間: 2025-3-25 00:18
Visas in international and municipal laws,ids (capsaicin and resiniferatoxin) are also an available therapeutic option, they are not regularly utilized due to their lack of FDA approval and documented efficacy and safety. The aim of this chapter is to describe the clinical applications of injectable intravesical agents for OAB and discuss their mechanism of action, outcomes, and safety.作者: 我不死扛 時(shí)間: 2025-3-25 03:34 作者: Esophagitis 時(shí)間: 2025-3-25 09:08
Outcome Measures and Patient Expectations for Overactive Bladder, that is expeditious, easy to understand, complete, and provides a thorough assessment of the patient satisfaction or outcome. Providers may consider utilizing shared decision-making to set realistic expectations and choose a practical outcome measure specific to one’s clinical practice to optimize patient care and satisfaction.作者: 爵士樂 時(shí)間: 2025-3-25 12:46
,β3-Agonists for Overactive Bladder,ticholinergics and placebo is also addressed in this review. A growing body of evidence suggests that mirabegron is a safe and efficacious drug with a limited side effect profile rendering it as a potential first-line pharmacological option for the management of OAB.作者: diathermy 時(shí)間: 2025-3-25 16:13 作者: 表主動(dòng) 時(shí)間: 2025-3-25 21:13
Individualizing Drug Therapy,ological properties of drugs, it also requires physicians and patients to have a candid discussion about treatment expectations in addition to counseling on drug side effects. Furthermore, patient comorbidities and age should be taken into consideration, as treatment should not create a hazardous situation for patients.作者: Synovial-Fluid 時(shí)間: 2025-3-26 01:05 作者: phase-2-enzyme 時(shí)間: 2025-3-26 04:29
Other Treatments for Overactive Bladder, Including Intravesical, intravesical therapies have been tested, many with positive results. In this chapter, we will present scientific trials of agents that have been tested in human subjects. Familiarity with these studies will expand the treatment armamentarium for practicing urologists, better enabling them to treat this challenging group of patients.作者: 挫敗 時(shí)間: 2025-3-26 11:39 作者: Creditee 時(shí)間: 2025-3-26 15:41 作者: hemoglobin 時(shí)間: 2025-3-26 20:08
Antimuscarinic Pharmacotherapy for Overactive Bladder,nts are in common use including darifenacin, fesoterodine, hyoscyamine, imidafenacin, propantheline bromide, scopolamine, solifenacin, tolterodine, trospium, flavoxate, and oxybutynin. Important clinical data on these drugs is summarized in this chapter.作者: misanthrope 時(shí)間: 2025-3-26 23:04
tten by experts in this fieldThis text provides a comprehensive, state-of-the art review of pharmacotherapy?for the overactive bladder, and serve as a valuable resource forclinicians, surgeons, and researchers with an interest in OAB. The early?chapters will describe the pathophysiology of OAB, algo作者: Cirrhosis 時(shí)間: 2025-3-27 02:17 作者: 外露 時(shí)間: 2025-3-27 06:06
https://doi.org/10.1007/3-540-28971-2 intravesical therapies have been tested, many with positive results. In this chapter, we will present scientific trials of agents that have been tested in human subjects. Familiarity with these studies will expand the treatment armamentarium for practicing urologists, better enabling them to treat this challenging group of patients.作者: amyloid 時(shí)間: 2025-3-27 12:21
Book 2019ans, surgeons, and researchers with an interest in OAB. The early?chapters will describe the pathophysiology of OAB, algorithm, and provide the readers with a practical guide for evaluating the OAB patient. The?next section describes the unique challenges involved in the study of OAB and helps the r作者: nonplus 時(shí)間: 2025-3-27 16:16
Considerations in Pediatric Overactive Bladder,or overactivity, and cure incontinence. Treatment follows a stepwise, multimodal approach including behavioral modification, adjunctive biofeedback, and in refractory cases, pharmacotherapy. This review will outline the pharmacologic treatment options for pediatric overactive bladder in cases where conservative management has proven unsuccessful.作者: 高談闊論 時(shí)間: 2025-3-27 19:02 作者: Nausea 時(shí)間: 2025-3-27 23:20 作者: Aggregate 時(shí)間: 2025-3-28 06:08
Book 2019hless?resource that provides a detailed account of the current evidence for the use of each of these therapies. The text concludes with chapters on unique populations with OAB,?and future directions in the research field..Contemporary Pharmacotherapy of Overactive Bladder?.unites?a unique set of tho作者: 察覺 時(shí)間: 2025-3-28 08:08
concludes with chapters on unique populations with OAB,?and future directions in the research field..Contemporary Pharmacotherapy of Overactive Bladder?.unites?a unique set of tho978-3-030-07328-2978-3-319-97265-7作者: 注意 時(shí)間: 2025-3-28 13:03 作者: 人類學(xué)家 時(shí)間: 2025-3-28 16:09
National and International Guidelines for Overactive Bladder, invasive testing in the uncomplicated patient and conservative treatments for first-line therapy and pharmacotherapy as effective second-line therapy. There are slightly more heterogeneous recommendations for invasive therapies for OAB. This chapter reviews the recommendations relating to pharmacot作者: 變形 時(shí)間: 2025-3-28 22:22
Combination Pharmacotherapy for Overactive Bladder,herapy of the above-mentioned two agents and also look in detail at the individual studies and comments on the subsequent meta-analysis that has been carried out so far, with particular reference not only to the results but also the potential adverse events seen. Based on this data, we provide real-作者: Interim 時(shí)間: 2025-3-29 01:28 作者: 我還要背著他 時(shí)間: 2025-3-29 03:03
Pharmacotherapy for Nocturia,ladder may be employed. NP is highly prevalent among patients with nocturia, however, and antidiuretic therapy should be considered when measures to address serious underlying etiologic conditions are ineffective.作者: Arable 時(shí)間: 2025-3-29 09:18
Future Considerations in Overactive Bladder Pharmacotherapy, in patients. One of the most promising is liposomes containing the toxin. OAB is a filling disorder, and ATP is involved in the generation of afferent impulses. Blocking the ATP pathway by P2X3 receptor antagonists works in animal models of lower urinary tract (LUT) dysfunction, but its clinical ef作者: 膽汁 時(shí)間: 2025-3-29 12:13
Considerations in Male Overactive Bladder,nation therapy has been shown to be both effective and safe. Despite deficits in our understanding of the pathophysiological connection between BOO and OAB, as well as often insufficient data to support a particular treatment regimen, the treatment options for LUTS are largely effective and safe. As作者: tympanometry 時(shí)間: 2025-3-29 19:38
Considerations in the Medically Complex and Frail Elderly,pter discusses what evidence exists for drug treatment of OAB-UUI in the medically complex and frail and the additional factors which might need to be taken into account in order to achieve the best outcomes from treatment.作者: GROVE 時(shí)間: 2025-3-29 21:25
Aspects of Quality: Laying the Foundations,approaches to try to manage the placebo response: the first approach was to enroll more severely affected patients, and the second approach was to use a larger study size to decrease the placebo response. Magnera et al. found that placebo led to a statistically significant improvement in four out of作者: Simulate 時(shí)間: 2025-3-29 23:56
Signals and Communication Technology invasive testing in the uncomplicated patient and conservative treatments for first-line therapy and pharmacotherapy as effective second-line therapy. There are slightly more heterogeneous recommendations for invasive therapies for OAB. This chapter reviews the recommendations relating to pharmacot作者: Celiac-Plexus 時(shí)間: 2025-3-30 07:36
Aspects of Quality: Laying the Foundations,herapy of the above-mentioned two agents and also look in detail at the individual studies and comments on the subsequent meta-analysis that has been carried out so far, with particular reference not only to the results but also the potential adverse events seen. Based on this data, we provide real-作者: 偏見 時(shí)間: 2025-3-30 09:31 作者: 個(gè)阿姨勾引你 時(shí)間: 2025-3-30 13:09 作者: Subjugate 時(shí)間: 2025-3-30 18:09
https://doi.org/10.1007/3-540-28971-2 in patients. One of the most promising is liposomes containing the toxin. OAB is a filling disorder, and ATP is involved in the generation of afferent impulses. Blocking the ATP pathway by P2X3 receptor antagonists works in animal models of lower urinary tract (LUT) dysfunction, but its clinical ef作者: Heterodoxy 時(shí)間: 2025-3-30 20:53
Visas in international and municipal laws,nation therapy has been shown to be both effective and safe. Despite deficits in our understanding of the pathophysiological connection between BOO and OAB, as well as often insufficient data to support a particular treatment regimen, the treatment options for LUTS are largely effective and safe. As作者: Madrigal 時(shí)間: 2025-3-31 01:48 作者: colostrum 時(shí)間: 2025-3-31 07:30
Diagnosis of Overactive Bladder,ne the condition as it has evolved over the past few decades. We will then review the basis for establishing a diagnosis, which includes a thorough symptom assessment as well as physical exam and urine studies. The use of adjunctive tests will also be reviewed, although their utility is limited in the diagnosis of an index patient with OAB.作者: 敵手 時(shí)間: 2025-3-31 12:14
Voice and Speech Quality Perceptionne the condition as it has evolved over the past few decades. We will then review the basis for establishing a diagnosis, which includes a thorough symptom assessment as well as physical exam and urine studies. The use of adjunctive tests will also be reviewed, although their utility is limited in the diagnosis of an index patient with OAB.作者: 使人入神 時(shí)間: 2025-3-31 15:08 作者: LIMN 時(shí)間: 2025-3-31 17:37
978-3-030-07328-2Springer Nature Switzerland AG 2019作者: 針葉類的樹 時(shí)間: 2025-4-1 01:09
Lindsey Cox,Eric S. RovnerProvides a comprehensive, state-of-the art review of pharmacotherapy for OAB.Provide practical algorithms for evaluating the OAB patient.Written by experts in this field作者: CURB 時(shí)間: 2025-4-1 02:48 作者: Minikin 時(shí)間: 2025-4-1 06:18
Voice and Speech Quality Perception, with or without urgency urinary incontinence, in the absence of urinary tract infection or other obvious pathologies. Various theories have been proposed to elucidate the pathophysiology of OAB. However, since the cause of OAB is often multifactorial and complex, there is not a unique and widely a作者: 富足女人 時(shí)間: 2025-4-1 12:18 作者: thyroid-hormone 時(shí)間: 2025-4-1 18:25
